References
- Tawbin JA, Bowles NE. The failing heart. Nature 2002; 415: 227–33
- Orlic D, Hill JM, Arai AE. Stem cells for myocardial regeneration. Circ Res 2002; 91: 1092–102
- Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292: 154–6
- Thomson JA, Itskovitz-Elder J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145–7
- Maltsev VA, Wobus AM, Robwedel J, et al. Cardiomyocytes differentiated in vitro from embryonic stem cells developmentally express cardiac-specific genes and ionic currents. Circ Res 1994; 75: 233–44
- Kehat I, Dorit KK, Snir M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108: 407–14
- Behfar A, Zingman LV, Hodgson DM, et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J 2002; 16: 1558–66
- Singla DK, Hacker TA, Ma L, et al. Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. J Mol Cell Cardiol 2006; 40: 195–2000
- Sachinidis A, Fleischmann BK, Kolossov E, et al. Cardiac specific differentiation of mouse embryonic stem cells. Cardiovasc Res 2003; 58: 278–91
- Roell W, Lu ZJ, Bloch W, et al. Cellular cardiomyoplasty improves survival after myocardial injury. Circulation 2002; 105: 2435–41
- Larsen TA, Goodsell DS, Cascio D, et al. The structure of DAPI bound to DNA. J Biomol Struct Dyn 1989; 7: 477–91
- Olivares EL, Ribeiro VP, Werneck de Castro JP, et al. Bone marrow stromal cells improve cardiac performance in healed infarcted rat hearts. Am J Physiol Heart Circ Physiol 2004; 287: H464–70
- Chedrawy EG, Wang JS, Nguyen DM, et al. Incorporation and integration of implanted myogenic and stem cells into native myocardial fibers: anatomic basis for functional improvements. J Thorac Cardiovasc Surg 2002; 124: 584–90
- Min J, Yang Y, Sullivan MF, et al. Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J Thorac Cardiovasc Surg 2003; 125: 361–9
- Hodgson DM, Behfar A, Zingman LV, et al. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol 2004; 287: H471–9
- Stripecke R, Carmen M, Skeiton D, et al. Immune response to green florescent protein: implications for gene therapy. Gene Ther 1999; 6: 1305–12
- Rosenzweig M, Connole M, Glickman R, et al. Inductor of cytotoxic T lymphocyte and antibody responses to enhanced green florescent protein following transplantation of transduced CD34+ hematopoietic cells. Blood 2001; 97: 1951–9
- Fukuda H, Takahashi J, Watanabe K, et al. Fluorescence-activated cell sorting-based purification of embryonic stem cell-derived neural precursors averts tumor formation after transplantation. Stem Cells 2006; 24: 763–71
- Shibata H, Ageyama N, Tanaka Y , et al. Improved safety of hematopoietic transplantation with monkey ES cells in the allogeneic setting. Stem Cells 2006;24:1450–7.
- Kehat I, Khimovich L, Caspi O, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004; 22: 1282–9
- Xue T, Cho HC, Akar FG, et al. Functional integrationally active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation 2005; 111: 11–20
- Zhang YM, Hartzell C, Narlow M, et al. Stem cell-derived cardiomyocytes demonstrate arrythmic potential. Circulation 2002; 106: 1294–9
- Fujikawa T, Oh SH, Pi L, et al. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol 2005; 166: 1781–91
- Fandrich F, Dresske B, Bader M, et al. Embryonic stem cells share immune-privileged features relevant for tolerance induction. J Mol Med 2002; 80: 343–50
- Fandrich F, Lin X, Chai GX, et al. Preimplantation-stage stem cells induce long-term allogenic graft acceptance without supplementary host conditioning. Nat Med 2003; 8: 171–8
- Li L, Baroja M, Majumdar A, et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells 2004; 22: 448–56
- Drukkera M, Katchmanb H, Katzc G, et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 2005; 24: 221–6
- Swijnenburg RJ, Tanaka TM, Vogel H, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005; 112(suppl 1)166–72
- Kofidis T, Jorg L, Tanaka M, et al. They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. Eur J Cardio-thorac Surg 2005; 28: 461–6
- Kofidis T, Darren LR, Swijnenburg R, et al. Allopurinol/uricase and ibuprofen enhance engraftment of cardiomyocyte-enriched human embryonic stem cells and improve cardiac function following myocardial injury. Eur J Cardio-thorac Surg 2006; 29: 50–5